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Abstract
Resistance to thyroid hormone (RTH) is a rare syndrome of reduced responsiveness of target tissues to thyroid
hormone and is caused mutation in the thyroid b receptor gene. We report a novel mutation, E445X, causing RTH
in a 4-year old girl. The patient exhibited extreme signs and symptoms of RTH at an early age, and had a large
compressive goiter. Following total extracapsular thyroidectomy, upper airway compression was relieved and
symptoms of hyperthyroidism improved. This case appears to be the youngest child recorded to have undergone
total thyroidectomy for RTH. Post-operative TSH elevations were managed with every-other-day triiodothyronine
therapy.
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Introduction
Resistance to thyroid hormone (RTH) is a rare syn-
drome of reduced responsiveness to thyroid hormone
that is caused by an alteration in the thyroid b receptor
gene [1,2]. The incidence of RTH is 1:40,000-50,000 live
births and inheritance is autosomal dominant [2,3]. De
novo mutation occur approximately 17% of cases, and
both males and females are equally affected [2]. RTH is
associated with elevated circulating levels of triiodothyr-
onine and thyroxine along with increased levels of thyr-
oid stimulating hormone (TSH) [1,2].
In response to TSH secretion thyroid enlargement
occurs in RTH [2]. In some situations, thyroid enlarge-
ment may result in upper airway compression. Learning
disabilities, developmental delay, tachycardia, attention-
deficit-hyperactivity disorder, and delayed skeletal
maturation are also seen in RTH [1,2]. We report a 4-
year old girl with upper airway compression due to
RTH caused by a novel mutation in the thyroid b recep-
tor gene. We also detail post-operative management
with every-other-day tri-iodothyronine.
Case Report
A four-year old female was found to have thyroid enlar-
gement by her primary care provider. At four years of
age, she was referred to a pediatric endocrinologist with
a large goiter causing compressive symptoms, including
sleep apnea and occasional inspiratory stridor. The child
had profound hyperkenesis and difficulty with concen-
tration. There was no family history of RTH.
At 4 years of age, the child was at the 40
th percentiles
for height and weight. The blood pressure was 112/61,
and the resting heart rate was 120 beats per minute. A
large goiter was present. Ultrasonography revealed a dif-
fusely enlarged gland without extension into the thor-
acic cavity. The estimated gland volume based on
ultrasonography was 150 ml.
The total T3 was > 2,000 ng/dL (normal range 80-180
ng/dL); the total T4 was 15.1 ug/dL (normal range 4-12
ug/dL); the free T4 was 1.8 ng/dL (normal 0.7-1.9 ng/
dL); the TSH was 60 mU/L (normal range 0.5-6 mU/L).
The skeletal age was 3 years at a chronological age of 3
years, 11 months. A magnetic resonance imaging (MRI)
study of the brain did not reveal any brain abnormalities
nor pituitary enlargement.
Genetic analysis revealed a novel mutation of the thyr-
oid receptor-b gene, E445X. This mutation introduces a
stop-codon in exon 10.
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day, which controlled the tachycardia and reduced the
hyperkinetic activity. A trial of triiodothyronine (LT3;
25-75 mcg per day) was not successful, as the child
developed abdominal pain, nausea, and worsening of her
behavioral symptoms. Thus, surgery was performed to
alleviate upper airway compression.
In preparation for surgery the patient was treated
orally with methimazole (10 mg per day) and supersatu-
rated potassium iodine solution for two weeks (3 drops,
t.i.d). Surgery was performed under general endotracheal
anesthesia. The thyroid gland was diffusely enlarged and
total thyroidectomy was performed preserving the para-
thyroid glands, recurrent laryngeal nerves and external
branches of the superior laryngeal nerves.
Pathological evaluation of the thyroid gland revealed a
125 gm specimen (Figure 1; normal for age 2 gm) [4].
The right lobe measured 8.5 × 5 × 3 cm, the left lobe
measured 9.5 × 5 × 3 cm, with an isthmus of 2.5 × 2 ×
1.6 cm. Histological examination demonstrated diffuse
papillary hyperplasia (Figure 2). Postoperatively, the
compressive upper airway symptoms resolved
immediately.
Postoperative treatment with LT3 was considered. Due
to parental concerns about the previous unfavorable trial
of LT3, treatment with levo-thyroxine (LT4) was begun.
On large doses of LT4 (175 mcg/day) the T4 was 19.6
ug/dl (252 nmol/L), the free T4 was 210 ng/dl (270
nmol/L); the total T3 was 210 ng/dl (3.2 nmol/L), and
the TSH measured 922 uIU/ml.
On the basis of observations in other patients with
severe RTH [5,6], LT3 therapy was introduced every
other day, with gradual dose escalations every few
months. After two years, TSH levels declined from levels
ranging between 900 to 1,000 uIU/ml, to about 300
uIU/ml when the every-other day dose reached 200 ug.
At this time, the heart rate was about 90 beats per min-
ute. Two year after surgery, a CT scan obtained when
the patient suffered mild-head trauma, indicated that
pituitary size was normal.
Discussion
Resistance to thyroid hormone (RTH) occurs as a result
f r o mam u t a t i o ni nt h eT Rb gene that encodes the
functionally relevant domain of T3-binding and its adja-
cent hinge region [1,2]. Our patient exhibited a novel
mutation resulting in RTH. E445X is a G to C nucleo-
tide change at position c1339 in exon 10 where the nor-
mal glutamic acid at position 445 of the protein is
changed to a stop codon. This mutation is expected to
result in a truncated TRb protein molecule.
Goiter development in RTH occurs as the result of
increased TSH secretion, and possibly increased TSH
action in RTH [1,2]. Medical therapy aims to suppress
TSH using daily LT3 therapy [1,2]. However, although
the child already had extremely elevated levels of T3, it
was not possible for the child to tolerate LT3 therapy.
Considering the compressive nature of the large amount
of thyroid tissue, surgery was performed.
Figure 1 Gross pathological specimen of the excised thyroid
gland. Specimen was 125 grams. The specimen is place on model
of an adult trachea that is 5-times larger than that of a 4-year old.
Figure 2 Histological image showing diffuse hyperplasia.
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children whose symptoms and goiter size cannot be
controlled medically [7-11]. The youngest individual
reported to have thyroidectomy for RTH that we are
aware of was a 9 year-old child homo-/hemizygous for
TR b gene mutation, with a goiter causing compressive
symptoms [11]. That individual exhibited severe psycho-
motor developmental delay, hearing loss, visual impair-
ment, chronic otitis media and tachycardia. She went
onto develop a recurrent goiter, requiring further surgi-
cal intervention at ages 13 and 16 [11].
To reduce this risk of goiter recurrence, we performed
an extracapsular total thyroidectomy. At two years after
surgery, no thyroid tissue was observed in imaging
studies.
Because of markedly elevated TSH levels and failure of
high-dose LT4 to results in significant TSH level reduc-
tions, the child was treated with escalating doses of LT3,
based on a reports showing that this strategy helps pro-
mote TSH level reductions, while attenuating the
adverse effects of LT3 [5,6]. After about two years,
when the LT3 dose reached 200 mcg every other day,
we observed major decrements in TSH, with no overt
symptoms of hyperthyroidism. Although central nervous
system imaging studies two years post-surgery did not
reveal pituitary enlargement, long-term evaluation will
be needed to assess if pituitary hyperplasia occurs. Inter-
estingly, even in the setting of persistently elevated high
TSH levels in individuals with RTH, pituitary hyperpla-
sia occurs seldom [12,13].
In sum, we report a novel mutation in the thyroid b
receptor gene leading to a compressive goiter. This
appears to be the youngest reported patient treated with
total extracapsular thyroidectomy for RTH. We also
detail post-operative management with every-other-day
LT3 with good results.
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